Synaptic Clefts Are Made to Be Crossed: Neurotransmitter Signaling in the Central Nervous System

Abstract

The primary means of communication between neurons in the mammalian central nervous system (CNS) is via release of chemical transmitters. Although the first transmitters to be discovered were the biogenic amines, such as acetylcholine and norepinephrine, involved in transmission in the autonomic nervous system, the contribution of other types of transmitters, such as amino acids and peptides, to CNS transmission has been the subject of recent study. Part of this interest stems from the relatively large percentage of neuronal connections that make use of amino acid transmitters such as gamma-aminobutyric acid and glutamate and also from the tremendous diversity possible when peptides are used as transmitters. Several disorders of CNS transmission are related to the degeneration of neuronal pathways in the brain. Two of the most prevalent neurologic disorders that result from degeneration are Alzheimer's and Parkinson's diseases. Aspects of these disorders related to chemical neurotransmission are discussed, along with implications with regard to therapeutic strategies. Functions of and possible abnormalities in amino acid transmission that may be associated with CNS disorders are examined. Several peptides are postulated to play a role in neurotransmission and concepts regarding the significance of the coexistence and release of biogenic amines and peptides at the same neuronal terminals are presented.

Keywords

Neurodegeneration dopamine acetylcholine peptides substance P opioids cytokines

References

Agid Y. , Javoy-Agid F. , Ruberg M. (1987). Biochemistry of neurotransmitters in Parkinson's disease. Mov Disord 2: 166-230.

Aimone LD , Yaksh TL (1989). Opioid modulation of capsaicinevoked release of substance P from spinal cord in vivo. Peptides 10: 1127-1131.

Bartfai T. , Iverfeldt K. , Fisone G. , Serfözö P. (1988). Regulation of the release of coexisting neurotransmitters . Annu Rev Pharmacol Toxicol 28: 285-310.

Baumgarten HG , Jenner S. , Björklund A. , Klemm HP , Schlossberger HG (1982). Serotonin neurotoxins. In: Biology of Serotonergic Transmission, Osborne NN (ed). Wiley, Chichester, UK, pp 249-277.

Campbell IL , Stalder Ak , Chiang CS , Bellinger R. , Heyser CJ , Steffensen S. , Masliah E. , Powell HC , Gold LH , Henriksen SJ , Siggins GR (1997). Transgenic models to assess the pathogenic actions of cytokines in the central nervous system. Mol Psychiatr 2: 125-129.

Coyle JT , Schwarcz R. (1976). Model for Huntington's chorea: Lesions of striatal neurons with kainic acid. Nature 263: 244-246.

Crawley JN (1985). Comparative distribution of cholecystokinin and other neuropeptides: Why is this peptide different from all other peptides? Ann NY Acad Sci 448: 1-8.

Dingledine R. , McBain CJ , McNamara JO (1990). Excitatory amino acid receptors in epilepsy. Trends Pharmacol Sci 11: 334-338.

Ensoli F. , Fiorelli V. , DeCristofaro M. , Santini MD , Novi A. , Vannelli B. , Thiele CJ , Luzi G. , Aiuti F. (1999). Inflammatory cytokines and HIV-1-associated neurodegeneration: Oncostatin-M produced by mononuclear cells from HIV-1-infected individuals induces apoptosis of primary neurons. J Immunol 162: 6268-6277.

10.

Feldman RS , Meyer JS , Quenzer LF (1997). Principles of Neuro-psychopharmacology. Sinauer, Sunderland, Massachusetts.

11.

Geula C. , Mesulam MM (1994). Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease. In: Alzheimer Disease , Terry RD , Katzman R , Lick KL (eds). Raven Press, New York, pp 263-291.

12.

Heikkila RE , Sonsalla PK , Duviosin RC (1989). Biochemical models of Parkinson's disease. In: Neuromethods, Drugs as Tools in Neuroscience Research, Vol 12, Boulton AB , Baker GB , Juorio AV (eds). Human Press, Clifton, New Jersey , pp 351-384.

13.

Helke CJ , Krause JE , Mantyh PW , Couture R. , Bannon MJ (1990). Diversity in mammalian tachykinin peptidergic neurons: Multiple peptides, receptors, and regulatory mechanisms. FASEB J 4: 1606-1615.

14.

Hornykiewicz O. , Pifl C. (1994). The validity of the MPTP primate model for the neurochemical pathology of idiopathic Parkinson's disease . In: Noradrenergic Mechanisms in Parkinson's Disease , Briley M , Marien M (eds). CRC Press, Boca Raton, Florida, pp 11-23.

15.

Licinio J. (1997). Central nervous system cytokines and their relevance for neurotoxicity and apoptosis. J Neural Transm Suppl 49: 169-175.

16.

McCann U. , Hatzidimitriou G. , Ridenour A. , Fischer C. , Yuan J. , Katz J. , Ricaurte G. (1994). Dexfenfluramine and serotonin neurotoxicity: Further preclinical evidence that clinical caution is indicated. J Pharmacol Exp Ther 269: 792-798.

17.

Molliver ME , Berger UV , Mamounas LA , Molliver DC , O'Hearn E. , Wilson MA (1990). Neurotoxicity of MDMA and related compounds: Anatomic studies. Ann NY Acad Sci 600: 640-664.

18.

Olanow CW , Kordower JH , Freeman TB (1996). Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci 19: 102-109.

19.

Pickel VM , Teitelman G. (1987). Immunocytochemistry of single and multiple antigens with special reference to the enzymes of catecholamine neurons. In: Monoaminergic Neurons: Light Microscopy and Ultrastructure, Steinbusch HWM (ed). Wiley, New York, pp 79-109.

20.

Roques BP , Beaumont A. , Dauge V. , Fournie-Zaluski MC (1993). Peptidase inactivation of enkephalins: Design of inhibitors and biochemical, pharmacological, and clinical applications . In: Opioids I, Handbook of Experimental Pharmacology, Vol 104, Herz A (ed). Springer-Verlag, New York, pp 547-584.

21.

Steinberg GK , Saleh J. , Kunis D. (1988). Delayed treatment with dextromethorphan and dextrorphan reduces cerebral damage after transient focal ischemia. Neurosci Lett 89: 193-197.

22.

Watling KJ , Krause JE (1993). The rising sun shines on substance P and related peptides. Trends Pharmacol Sci 14: 81-84.

23.

Woodruff GN , Hughes J. (1991). Cholecystokinin antagonists . Annu Rev Pharmacol Toxicol 31: 469-501.